Advanced search
Publication Cover
Journal of Blood Medicine Volume 7, 2016 - Issue
Submit an article Journal homepage
100
Views
14
CrossRef citations to date
0
Altmetric
Review

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A

Pratima Chowdary1 Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UKCorrespondence[email protected]
,
Emma Fosbury1 Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK
,
Anne Riddell1 Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK
&
Mary Mathias1 Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK;2 Haemophilia Centre, Great Ormond Street Hospital for Children, London, UK
Pages 187-198 | Published online: 12 Sep 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Cassandra P. Wang, Guy Young & Courtney D. Thornburg. (2021) Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opinion on Drug Safety 20:4, pages 387-396.
Read now
Kenneth Lieuw. (2017) Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?. Journal of Blood Medicine 8, pages 67-73.
Read now

Articles from other publishers (12)

Tine M.H.J. Goedhart, A. Janssen, Ron A.A. Mathôt & Marjon H. Cnossen. (2023) The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators. Blood Reviews 61, pages 101098.
Crossref
Nana Kragh, Anna Tytula, Michał Pochopien, Samuel Aballéa, Mondher Toumi, Zalmai Hakimi, Jameel Nazir, Linda Bystrická & Francis Fatoye. (2022) Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK . European Journal of Haematology 110:3, pages 262-270.
Crossref
Ankit Javia, Jigar Vanza, Denish Bardoliwala, Saikat Ghosh, Late Ambikanandan Misra, Mrunali Patel & Hetal Thakkar. (2022) Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview. International Journal of Pharmaceutics 623, pages 121863.
Crossref
Suresh Katragadda, Srividya Neelakantan, Lei Diao & Nancy Wong. (2021) Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects. The Journal of Clinical Pharmacology 61:7, pages 889-900.
Crossref
Alanna McEneny‐King, Pierre Chelle, Margaret H. Goggans, Patricia J. Barker, Timothy W. Jacobs, Ellis J. Neufeld, Ulrike M. Reiss & John C. Panetta. (2021) Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients. Haemophilia 27:3, pages 408-416.
Crossref
Beatrice Nolan, Johnny Mahlangu, Ingrid Pabinger, Guy Young, Barbara A. Konkle, Chris Barnes, Keiji Nogami, Elena Santagostino, K. John Pasi, Liane Khoo, Bent Winding, Huixing Yuan, Joachim Fruebis, Dan Rudin & Johannes Oldenburg. (2020) Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia 26:3, pages 494-502.
Crossref
Martin Rodriguez, Christopher D. Porada & Graça Almeida-Porada. (2019) Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A. Current Stem Cell Reports 5:4, pages 145-161.
Crossref
Anita Shah, Alexander Solms, Sara Wiegmann, Maurice Ahsman, Erik Berntorp, Andreas Tiede, Alfonso Iorio, Maria Elisa Mancuso, Tihomir Zhivkov & Toshko Lissitchkov. (2019) Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology 98:9, pages 2035-2044.
Crossref
Pratima Chowdary, Manuel Carcao, Pål A. Holme, Victor Jiménez‐Yuste, Steven R. Lentz, Judi Møss, Lone H. Poulsen, Chunduo Shen, Alberto Tosetto, Allison Wheeler & Elena Santagostino. (2019) Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis 3:3, pages 542-554.
Crossref
S. Mangles, C. Rea, B. Madan, E. I. Nielsen, S. Jönsson, J. Needham, P. W. Collins & S. Rangarajan. (2018) Real life experiences of a PK dosing study-Challenges and lessons learned.. Haemophilia 24:3, pages e145-e148.
Crossref
A. Markin A. & L. Dubey L.. (2018) AGE PECULIARITIES OF PSYCHOSOCIAL DETERMINANTS OF THE COURSE OF SEVERE FORMS OF HEMOPHILIA A IN CHILDREN. Bulletin of Problems Biology and Medicine 1:2, pages 67.
Crossref
Alexandra Sherman, Moanaro Biswas & Roland W. Herzog. (2017) Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A. Frontiers in Immunology 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.